en · de · es · fr · pt
peptide-index.peptides7501.com › Guide › Sr9009 Identity And Mechanism — Evidence Review

Sr9009 Identity And Mechanism — Evidence Review

By Editorial Desk · published 2025-12-30 · last reviewed 2026-02-13 · Guide

A practical reference on nuclear receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-02-13. Anything still debated is marked as such rather than presented as settled.

SR9009 Identity and Mechanism

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

Background and Receptor Pharmacology

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Sr9009 at a glance

PropertyValueNotes
Common nameSR9009Also marketed informally as Stenabolic
Chemical classSynthetic REV-ERB agonistBinds REV-ERBα and REV-ERBβ
Molecular formulaC24H30ClN3O4SApproximate molecular weight 492 g/mol
CAS Registry Number1379686-30-2Identifier for the parent compound
Regulatory statusNot approved for human useProhibited in sport by WADA

Identity, Handling, and Regulation

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

Related pages on this site

Analytical Detection and Stability

Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Background from the literature

RTI-5152-12, or WW-12 (in patent), is a synthetic small-molecule agonist of the atypical chemokine receptor ACKR3 (CXCR7) that was derived from the naturally occurring alkaloid conolidine. RTI-5152-12 has 15-fold improved potency towards ACKR3 relative to conolidine. ACKR3 is a novel opioid receptor which functions as a broad-spectrum trap or scavenger for endogenous opioid peptides, including enkephalins, dynorphins, and nociceptin. The receptor acts as a negative modulator of the opioid system by decreasing the availability of opioid peptides for their classical receptors like the μ-opioid receptor. Ligands of ACKR3, by competitively displacing endogenous opioid peptides from ACKR3, can potentiate the actions of these endogenous opioids and produce effects like analgesia and anxiolysis in animals. RTI-5152-12 is being developed as a potential pharmaceutical drug and, as of December 2021, is in the preclinical stage of development for treatment of pain. The chemical structure was not disclosed until a patent was published in June 2022.

=== Football-only alignment (2020-2025) === In February 2019, in conjunction with the Wisconsin Football Coaches Association, the WIAA released a sweeping football-only realignment for Wisconsin to commence with the 2020 football season and run on a two-year cycle. The East Central Conference retained six members for football (Berlin, Kettle Moraine Lutheran, Kewaskum, Plymouth, Ripon and Waupun) and welcomed two football-only members: Port Washington of the North Shore Conference, and Sheboygan Falls of the Eastern Wisconsin Conference. This alignment remained in place for the 2022-2023 realignment cycle. For the 2024-2025 cycle, the East Central Conference was whittled down to six members, with returnees Kettle Moraine Lutheran, Kewaskum, Plymouth and Port Washington being joined by Beaver Dam and Watertown of the Badger Conference. The East Central Conference was realigned out of existence for the 2026-2027 realignment cycle.

=== Other characters === Nazuna (薺, Nazuna) Voiced by: Nao Toyama (Japanese); Sarah Wiedenheft (English) A little girl Hinagiku and Sakura meet while climbing Ryugu Peak. Her dramatic story prompts Hinagiku to perform the ritual of the Spring Manifestation. The little girl thus becomes the first witness of the return of Spring.

Simon enters the previously chained-up apartment and, after a long hallway where he hears a doctor describing an encounter with his patient and being attacked yet again, finds the fuses. While attempting to retrieve the fuses again to open a gate for a train, he enters another nightmare where he is chased through a maze by monsters hanging from the ceiling, escaping through a door that opens back up to a completely different hallway. After boarding the train, Simon is attacked by monsters yet again, and the train eventually crashes and derails, causing him to lose all of his belongings. As the train is about to fall off a cliff, Simon narrowly escapes and finds himself in a dark forest. Deep in the forest, Simon discovers an asylum as the doctor enters. Simon finds the doctor behind a gate where the doctor orders him to hand him a new gun in exchange for letting him pass. Simon can either oblige or refuse, but regardless, the doctor ends up betraying Simon and shoots him (with a greater penalty to maximum health if Simon complied). Simon eventually kills the doctor after a gunfight. Simon leaves the forest and rows a boat across a lake to his hometown. He finally reaches his house and expects his mother to be waiting for him, but the house is empty. He enters his bedroom and finds a book. Through a flashback, the player finds out that the entire story was a figment of Simon's imagination. After the car crash, Simon became reliant on a wheelchair. Depressed, his therapist (who was the doctor in the game) advised him to document his feelings in a book.

Sources: en.wikipedia.org

Further detail

=== Skinny Revolution === Pickston founded Skinny Revolution to help people to lose weight after she gained 7 stone in 14 months, partly whilst pregnant, using a Wegovy (semaglutide) injection, which is a 2.4 mg injectable prescription medicine used as an appetite suppressant.

== Alternatives == A variety of other calculations have been done based on similar parameters to determine the risk of mortality in acute liver failure. The Acute Physiology and Chronic Health Evaluation II (APACHE II) score has a comparable sensitivity to the King's College Criteria in determining prognosis.

== External links == Amino acid metabolism Chapter on Amino acid catabolism in Biochemistry by Jeremy Berg, John Tymoczko, Lubert Stryer. Fourth ed. by Lubert Stryer. ISBN 0-7167-4955-6 Accessed 2007-03-17 Amino acid metabolism

Ion mobility spectrometry (IMS) is a method of conducting analytical research that separates and identifies ionized molecules present in the gas phase based on the mobility of the molecules in a carrier buffer gas. Even though it is used extensively for military or security objectives, such as detecting drugs and explosives, the technology also has many applications in laboratory analysis, including studying small and big biomolecules. IMS instruments are extremely sensitive stand-alone devices, but are often coupled with mass spectrometry (MS), gas chromatography or high-performance liquid chromatography (HPLC) in order to achieve a multi-dimensional separation. They come in various sizes, ranging from a few millimetres to several metres depending on the specific application, and are capable of operating under a broad range of conditions. IMS instruments such as microscale high-field asymmetric-waveform ion mobility spectrometry can be palm-portable for use in a range of applications including volatile organic compound (VOC) monitoring, biological sample analysis, medical diagnosis and food quality monitoring. Systems operated at higher pressure (i.e. atmospheric conditions, 1 atm or 1013 hPa) are often accompanied by elevated temperature (above 100 °C), while lower pressure systems (1–20 hPa) do not require heating.

The Canada Games is the country's highest-level youth multi-sport event held every two years. Canada has enjoyed success both at the Winter Olympics and the Summer Olympics—particularly the Winter Games as a "winter sports nation". Canada has hosted high-profile international sporting events such as the 1976 Summer Olympics, the 1988 Winter Olympics, the 2010 Winter Olympics, multiple Commonwealth Games, the 2015 FIFA Women's World Cup, the 2015 Pan American Games and 2015 Parapan American Games. The country co-hosted the 2026 FIFA World Cup alongside Mexico and the United States.

Sources: en.wikipedia.org

Background from the literature

1. The synthesis of isopentenyl pyrophosphate, the "building block" of cholesterol 2. The formation of squalene via the condensation of six molecules of isopentenyl phosphate 3. The conversion of squalene into cholesterol via several enzymatic reactions

==== Heating ==== A report given to the Food and Drug Administration by the Institute of Food Technologists thoroughly discusses the thermal processing of food. A notable step in development of heat application to food processing is pasteurization, developed by Louis Pasteur in the nineteenth century. Pasteurization is used to kill microorganisms that could pose risks to consumers or shorten the shelf life of food products. Primarily applied to liquid food products, pasteurization is regularly applied to fruit juice, beer, milk, and ice cream. Heat applied during pasteurization varies from around 60 °C to kill bacteria to around 80 °C to kill yeasts. Most pasteurization processes have been optimized recently to involve several steps of heating at various temperatures and minimize the time needed for the process. A more severe food heating mechanism is thermal sterilization. While pasteurization destroys most bacteria and yeast growing in food products, the goal of sterilization is to kill almost all viable organisms found in food products including yeast, mold, bacteria, and spore forming organisms. Done properly, this process will greatly extend the shelf life of food products and can allow them to be stored at room temperature. As detailed in The Handbook of Food Preservation, thermal sterilization typically involves four steps. First, food products are heated to between 110 and 125 °C, and the products are given time for the heat to travel through the material completely.

Elevated copper levels inside a cell cause oxidative stress and generate hydrogen peroxide. Under these conditions, copper participates in the so-called Fenton-type reaction — a chemical reaction causing oxidative damage to cells. Excess copper interferes with microbial cell membrane integrity, leading to leakage of specific essential cell nutrients, such as potassium and glutamate. This leads to desiccation and subsequent cell death. While copper is needed for many protein functions, in an excess situation (as on a copper alloy surface), copper binds to other proteins that do not require copper. This "inappropriate" binding leads to loss-of-function of the protein, and/or breakdown of the protein into nonfunctional portions.

The Scottish Government reaffirms its wish to see the Gender Recognition Reform (Scotland) Bill enacted. 11 May – Scotland's warmest day of the year so far is recorded by the Met Office, with a temperature of 25.7 °C at Cassley. 13 May – At the High Court in Kilmarnock, Uber driver Kunathilinghan Mohanthas is sentenced to seven years in prison for killing Christopher Hanton, who he left for dead in Glasgow city centre after ordering him out of his car and knocking him over as he performed a three-point turn in August 2023. 14 May – MSPs unanimously approve the Housing Cladding Remediation Bill with 116 votes in favour of the legislation that seeks to address problems with cladding on buildings and avoid a similar incident to the Grenfell Tower fire in Scotland. 15 May – The Scottish Government declares a national housing emergency during a parliamentary debate at Holyrood, citing UK government budget cuts and austerity as the reasons for a shortage in housing. Justice Secretary Angela Constance confirms that the Scottish Government are to seek powers to facilitate the early release of prisoners in order to prevent overcrowding in prisons. The rules would only apply to those serving under four years and would not apply to those convicted of sexual or domestic violence related offences. 18 May – Four police officers are injured and 19 arrests made in Glasgow city centre as fans celebrate after Celtic win the Premiership.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.

Is SR9009 approved for human use?

No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.

Why is SR9009 banned in sport?

The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.

What is SR9009?

SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.

Network